GW Pharmaceuticals CEO: Pot-based epilepsy drug trial has taken a ‘huge step’

Epidiolex is an orphan drug that is pharmaceutical cannabidiol, not medical marijuana. The drug helps treat various types of pediatric epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome. GW Pharma’s study revealed that patients taking 20 mg of Epidiolex had a medium reduction in monthly seizures of 42 percent versus a 17 percent reduction for those on placebo.

“The good news is this is actually the third positive trial within the field of treatment resistant childhood onset epilepsy that we have reported results for in the last six months,” Gover said.

The company said it expects to file a new drug application with the FDA in the first half of 2017. GW Pharma is a U.K. based biotech that grows its own cannabis plants — the scientific name for marijuana — to study the ingredients, and then synthesizes it into medicine.

... read more at: http://www.cnbc.com/2016/09/26/gw-pharmaceuticals-ceo-pot-based-epilepsy-drug-trial-has-taken-a-huge-step.html

by